Tag: Dr. Matthew Kulke

News about Neuroendocrine Cancer Expert Physicians

Three appointments and a newly established one-year neuroendocrine tumor (NET) fellowship herald an exciting new year for several NET specialists.

Edward M. Wolin, MD, Co-Medical Director of the Carcinoid Cancer Foundation, has been named Director…

Neuroendocrine Tumors on TV: Rare Disease Day Special, February 28, 2017

NETs on TV!  The Carcinoid Cancer Foundation has teamed up with The Balancing Act and Advanced Accelerator Applications to raise awareness about carcinoid and neuroendocrine tumors (NETs) during a feature on Lifetime TV on February 28 (Rare Disease…

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, April 2016

Rare Neuroendocrine Skin Cancer Treated by Immunotherapy

Merkel cell carcinoma, a rare neuroendocrine virus-linked skin cancer, has been added to the list of cancers that can be treated by immunotherapy. Scientists who led the clinical study of the…

OncLive Features Neuroendocrine Tumors in Videos and News Articles

Chemotherapy Options in Neuroendocrine Tumors is the latest video to be released in the OncLive series on Neuroendocrine Tumors. Matthew H. Kulke, MD, Director of the Program in Neuroendocrine and Carcinoid-Tumors at Dana-Farber/Brigham and Women’s…

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community

As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …

Neuroendocrine Tumors Focus of Upcoming Issue of Hematology/Oncology Clinics

Neuroendocrine Tumors will be featured in the February 2016 issue of Hematology/Oncology Clinics. Dr. Jennifer Chan and Dr. Matthew Kulke, both from Dana-Farber Cancer Institute in Boston, Massachusetts are Editors of the issue, published by Elsevier.…

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

• PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society

March 30 Is National Doctors’ Day

March 30 is NATIONAL DOCTORS’ DAY. In recognition of carcinoid/neuroendocrine tumor (NET) doctors – you are our heroes and superheroes!! Pictured are some of the NET specialists throughout the United States.

Pictured by columns, left to right, top …